cyrilzakka/clinical-trials huggingface dataset:
Music Therapy and Bio-psychological Effect Among Chronic Psychiatric Inpatients of a Community Teaching Hospital

Negative symptoms are an important factor in preventing patients from returning to the community, we aim to assess the effect of music therapy on negative symptoms through this study. Participants of integrated music therapy will receive instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process. Other participants will receive passive music listening or regular occupational therapy during the experimental period. Psychiatric symptoms, quality of life, social and interactive skills, and the differences in the physiological signals produced by skin, muscles, and heart will be measured before, after, and two months after the music therapy.

Music therapy is gradually being used in the field of psychiatry, such as depression, anxiety, and development disorders in children. However, music therapy still lacks systematic research on chronic mental illness. Since negative symptoms are an important factor in preventing patients from returning to the community, we aim to assess the effect of music therapy on negative symptoms through this study. Additionally, Taiwan as many Asian countries have not yet established a certification system for music therapy. This study cooperates with licensed therapists abroad in the hope of promoting the systematic development of local music therapy in the future.

Participants of integrated music therapy (Group 1, integration of active and passive music therapy) includes instrument playing, singing, lyrics modification/music organized play, listening to music and discussing each treatment process. The four stages of activities are warm-up, main activities, secondary activities, and the ending section. The participants of the music listening group (Group 2, background music listening), music selection based on the musical preference and background of subjects, for relax or boost the spirit of the subjects. Participants in the control group (Group 3) receive their regular occupational therapy during the experimental period. We plan to recruit 100 people in the wards: 40/20/40 (Group 1/2/3) under random assignment.

To evaluate the effects of three groups, we measure their psychiatric symptoms, quality of life, social and interactive skills, and the differences in the physiological signals produced by skin, muscles, and heart assisted by a medical engineering scholar before, after, and two months after the music therapy.

Eligibility Criteria:
Inclusion criteria

* Chronic patient in rehabilitation ward without compulsory hospitalization.
* Patients with mental, behavioral and neurodevelopmental disorders, including schizophrenia, schizotypal personality disorders, delusional disorders, affective disorders, and organic mental disorders.

Exclusion criteria

* Patients with hearing impairments.
* Patients with no capacity to make juridical acts.
Topical CBD Scar Healing Study

CBD has anti-inflammatory properties, and it interacts with skin receptors that help keep the skin healthy. This is why, investigators are looking into using CBD oil on forehead scars to see if it makes scars look better.

Investigators are planning to evaluate the subjective and objective impact of CBD oil on scar healing outcomes, specifically focusing on postoperative scars resulting from paramedian forehead flap reconstruction. The study will employ a split-scar randomized control trial with established outcome measurement tools. Prospective participants undergoing this procedure will be enrolled, with the vertical forehead scar as the primary area of interest.

Participants will be randomly assigned to one of two groups: the control group, which will receive treatment with a silicone patch only, or the experimental group, which will receive a combination of CBD oil and a silicone patch. The allocation of treatment to the top or bottom vertical half of the scar will be randomized for each patient.

Participants will be monitored for a duration of 6 months, during which they will complete the Modified Patient and Observer Scar Assessment Scale at each postoperative visit. After the 6-month period, a blinded rater will evaluate photographs of the scars using the Scar Cosmesis and Rating Scale, without knowledge of the treatment received.

Eligibility Criteria:
Inclusion Criteria

• Patients that are adults (18+) of all genders and ethnicities who have undergone a PMFF (Paramedian forehead flap) will be considered for this study.

Exclusion Criteria

* Patients younger than 18 years of age
* Patients with known allergies to CBD

Termination criteria

• There will be immediate termination from the study if any allergic response to the CBD/silicone combination occurs or if the topical application of CBD/silicone significantly worsens the scar outcome at the Follow Up 2 visit or at any subsequent visit. ii. If the patient voluntarily requests cessation in the study.
Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer

The overall objective of this study is to determine whether high-resolution imaging of the esophagus during routine diagnostic upper endoscopy can assist clinicians in detecting and discriminating dysplastic (precancerous) areas. This high-resolution microendoscope (HRME) was developed by our collaborators at Rice University and provides \> 1000x magnified images of the esophageal mucosa. The purpose of this study is to determine whether this device can be used to enhance the diagnostic accuracy of routine endoscopic screening for squamous cell cancer of the esophagus.


Eligibility Criteria:
Inclusion Criteria:

* known or suspected squamous cell neoplasia
* 18 years or older
Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers

Phase I study to evaluate the excretion of radioactivity, the metabolic profile, pharmacokinetics, safety and tolerability following a single oral administration of \[14C\] Prucalopride Succinate in healthy male volunteers aged 18 to 50 years (inclusive).The purpose of this study is to investigate how and how quickly Prucalopride Succinate or its break down products are excreted by analysing blood, faeces and urine samples collected during the study.


Eligibility Criteria:
Inclusion Criteria:

* Males aged between 18 and 50 years, inclusive
* Body mass index (BMI) of ≥18 and ≤30 kg/m2
* No more than 2 bowel movements per day or fewer than 3 bowel movement per week
* Provision of signed and dated, written informed consent prior to any study specific procedures

Exclusion Criteria:

* Have participated in a \[14C\]-study within the last 6 months.
* Exposure to clinically significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring).
* Male subjects who consume more than 21 units of alcohol per week or 3 units per day.
Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia

ACCURATE will test the hypothesis that opportunistic genetic testing for Familial Hypercholesterolemia (FH) in patients admitted to hospital with an acute coronary syndrome will increase the diagnosis of FH and will impact patient care and outcomes. The study will recruit patients admitted to hospital with an acute coronary syndrome, and research-based genetic testing will be conducted for known FH-causing genetic variants. The results will be returned to the patients' treating physicians. The primary endpoint will be the number of patients with a new diagnosis of FH. The secondary endpoints will be the proportion of patients who undergo intensification of lipid-lowering therapy, the lowest LDL cholesterol level achieved, and the proportion of patients reaching guideline recommended lipid targets in the 12 months after the index acute coronary syndrome.

Familial hypercholesterolemia (FH) is an inherited condition characterized by elevated low-density lipoprotein cholesterol (LDL-C) levels and premature atherosclerotic cardiovascular disease (ASCVD). Despite being the most common inherited cardiovascular disorder, it is still highly underdiagnosed and undertreated worldwide. The Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia (ACCURATE) study was designed to test the hypothesis that opportunistic genetic testing for FH among patients hospitalized for acute coronary syndrome (ACS) will increase the diagnosis of FH and improve patient outcomes. ACCURATE is a non-randomized, controlled trial of patients \<60 years old admitted to an acute cardiac unit with ACS and elevated LDL-C levels. The first cohort will consist of a control group of patients presenting with ACS who will be treated according to usual standard-of-care. The second cohort will consist of patients presenting with ACS in whom research-based genetic testing for FH will be performed during hospitalization and the results returned to the treating physicians. The primary endpoint will be the number of patients with a new diagnosis of FH. The secondary endpoints will be the proportion of patients who undergo intensification of lipid-lowering therapy, the lowest LDL-C level achieved, and the proportion of patients reaching guideline recommended lipid targets in the 12 months after the index ACS. ACCURATE represents the first clinical trial of genetic testing for FH in the acute cardiac care setting and is expected to help identify optimal approaches to increase the diagnosis and treatment of FH.

Eligibility Criteria:
1. Age \<60 years

   AND
2. Admitted to an acute cardiac unit with either:

   * A ST elevation myocardial infarction (STEMI), or
   * A non-ST elevation myocardial infarction (NSTEMI)

   AND
3. Maximum lipid level at the time of admission or during the prior 1 year of

   * LDL level ≥4 mmol/L (154 mg/dL) if not on a statin, or
   * LDL-C level ≥2.5 mmol/L (96 mg/dL) if on a statin prior to presentation, or
   * Non-HDL-C ≥4.6 mmol/L (177 mg/dL) if LDL-C not available
Dyspnea Neuroscience Education on Patients With Chronic Obstructive Pulmonary Disease

The principal aim of this study was to adapt pain neuroscience education to dyspnea, Dyspnea Neuroscience Education (DNE), and measure its effect on dyspnea perception, physica l activity level, disability, quality of life and ventilatory and functional capacity through a randomized controlled trial. The secondary objectives were to evaluate its feasibility and its effect on emotional state (anxiety and depression), medical atten dance, number of exacerbations and the willingness to exercise.


Eligibility Criteria:
Inclusion Criteria:

* Diagnostic of COPD by a physician or pneumologist
* Stage 1, 2 or 3 on the GOLD Classification
* GOLD Stage and FEV1 assessed by a physician in the last three months
* Access to a computer and internet

Exclusion Criteria:

* Cognitive impairment (MoCA-S score \< 21)
* Depression disorder (PHQ-9 score ≥11)
* Generalized Anxiety Disorder (GAD-7 score ≥10)
* Instable comorbidities preventing physical activities
* Had a surgery in the past three months
* Had an exacerbation in the past three months
* Currently quitting tobacco
* Use of oxygenation
Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study

To evaluate the safety and efficacy on clinical symptoms, mucosal histology and endoscopic mucosal appearance of two doses of SR140333B against placebo in patients with mild to moderate ulcerative colitis resistant to treatment with 5-ASA.

Patients with active mild to moderate ulcerative colitis that has not responded to a minimum of 4 weeks of 5-ASA will be randomized to receive single daily doses of either placebo, 600 mg SR140333B or 1800 mg of SR140333B for eight weeks. Patients will undergo baseline and end of study sigmoidoscopic assessments and complete daily symptom diaries during the study. Ulcerative colitis disease activity will be measured by both the overall and component subscores of the Mayo Disease Activity Index.

Eligibility Criteria:
Inclusion Criteria:

* Age at least 18 years
* Ulcerative colitis of at least 6 months duration
* Patient's ulcerative colitis should remain active while taking 5-ASA or sulfasalazine for at least 4 week
* If taking corticosteroids, dose must be stable for at least 2 weeks prior to enrollment and not exceed 20 mg per day (prednisolone equivalent)

Exclusion Criteria:

* Crohn's disease
* Colonic dysplasia
* Stool culture positive for enteric pathogens
* Concurrent cancer or unstable medical condition
* Recent treatment with monoclonal antibody
* Recent introduction of thiazolidinedione
* Recent treatment with methotrexate or cyclosporine
* Recent treatment with an antibiotic prescribed for ulcerative colitis
A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.

The main objective of the study is to investigate the safety and efficacy of Replenine®-VF administered by continuous infusion in appropriate dosage to prevent bleeding and achieve haemostasis in patients with haemophilia B undergoing major surgery.


Eligibility Criteria:
Inclusion Criteria:

* Patients with moderate to severe Haemophilia B (≤5% baseline Factor IX level) due to undergo major surgery, previously treated patients, at least 16 years of age without inhibitors, currently receiving Factor IX concentrate.

Exclusion Criteria:

-
Cold and Warm Water for Performance Recovery

The overall aim of this study is, to evaluate the effectiveness of repeated cold- and warm water immersion on performance recovery after muscle damage.

Participants perform a muscle-damage protocol, which comprises 5x20 drop jumps. After the exercise protocol is finished, the participants will undergo one of three recovery interventions. Cold-water immersion, Warm-water immersion or the control-intervention. During the exercise protocol and the recovery intervention following parameters will be assessed: Blood oxygenation, Muscle oxygenation, heart-rate, skin temperature and core temperature.

Then, performance recovery will be assessed during the following 72 hrs (in a 24 hrs interval).

At each time-point, following measurements will be conducted: vertical-jump performance, maximum voluntary isometric contraction of the m.quadriceps femoris muscle, muscle swelling and delayed-onset of muscle soreness.

Eligibility Criteria:
Inclusion Criteria:

* Healthy participants
* No surgeries
* No previous injuries
* Anticonceptiva allowed

Exclusion Criteria:

* Acute injuries or current pain situations
* Cryophobia
* Fear
* Pregnancy
* Raynaud syndrome
* Medication intake
Added Sugar Intake, Sweet Taste Phenotypes and Biomarkers

The goals of this cross-sectional study on a racially diverse group of children (3-10y) and their mothers are to determine whether the relationship between sweet taste phenotypes differed among mother-daughter and mother-son dyads and to determine the predictive value of a hair biomarker (delta13C). Given the widespread overconsumption of added sugars, and the associated burden of disease, improving surveillance measures and developing strategies to reduce added sugar intake, especially among the youngest members of society, are public health priorities.

This is a single-site cross-sectional study designed to investigate the relationship of sweet taste phenotypes among mother-child dyads and assess the predictive value of a hair biomarker for sweet taste phenotypes. For each participant, we will collect 2-day 24-hour dietary recalls to determine added sugar intake; directly assess the level of sweet taste most preferred; measure liking/disliking of sweet tasting foods and beverages; collect anthropometric measures; and collect at least 3 cm of hair for biomarker analyses. Mothers will also complete a variety of questionnaires on parenting and child behavior.

Eligibility Criteria:
Inclusion Criteria:

* Hair that is greater than or equal to 3 cm in length
* Child is between the ages of 3 and 10 years and adult is between the ages of 18 and 70
* Access to electronic device including Smartphone, iPad, tablet, laptop, or desktop computer for participation in remote study visits.

Exclusion Criteria:

* Diagnosis of Type 2 Diabetes
I2-CoRT WTP9: Upper Extremity Motor Intervention, Use of Hand Orthosis in People Post-stroke

The upper extremity kinematics of people post-stroke will be monitored with/without an inactive hand orthosis (intervention: added weight to hand) during ARAT, Fugl-Meyer, and Box and Blocks tests. Measurements will occur right after inclusion and repeated once after 7-8 weeks. Upper extremity kinematics and test scores will indicate the influence of additional weight to hand as a possible confounder when, in the future, the hand orthosis would be used as a therapy tool.


Eligibility Criteria:
Inclusion Criteria:

* Post-stroke
* Receive regular therapy at Jessa hospital
* Able to willingly sign informed consent

Exclusion Criteria:

* Relapse during study
* Secundary complications limiting upper extremity performance
F-18 PET Bone Scans Versus Tc-99m Bone Scans for the Diagnosis of Bone Metastases

The purpose of this study is to compare 18F-Fluoride PET bone scans to traditional 99mTc-MDP bone scan to determine if one is better for diagnosing bone metastases.

Compare the diagnostic sensitivity, specificity, and accuracy of 18F-Fluoride PET bone scans versus traditional 99mTc-MDP bone scans for detecting bone metastases.

Determine if there is a significant change in clinical management between the two types of scans.

Measure and compare the number of equivocal or uncertain findings that would have caused additional testing, particularly additional imaging studies, to be performed for confirmation when using 18F-Fluoride PET bone scans versus 99mTc-MDP bone scans.

To quantify any adverse events resulting from either scan.

To perform subgroup analyses according to cancer cell type.

Eligibility Criteria:
Inclusion Criteria:

* Patient has cancer
* Has been referred for evaluation of bone metastases
* Patient or patient's legal representative can understand and consent to enrollment in the study
* Must be 18 years or older
* Can remain still during the scan (approximately one hour)
* Patient has Medicare

Exclusion Criteria:

* Patient does not have Medicare
* Under the age of 18
* Cannot lie still for the necessary time
A Study Comparing Continuous Sciatic Nerve Block to Single Shot Sciatic Nerve Block

The purpose of this study is to compare the incidence of postoperative symptoms of neurologic injury after a single shot infragluteal-parabiceps sciatic nerve block versus a continuous infragluteal-parabiceps sciatic nerve catheter.

There are a limited number of prospective studies in the literature examining the risk of neurologic injury and symptoms after sciatic nerve blocks. The incidence of transient neurological symptoms after a continuous catheter is not well reported.

Eligibility Criteria:
Inclusion Criteria:

* all patients ( ≥18 and ≤ 80) who are scheduled to undergo elective scheduled foot surgery and agreed to receive a sciatic nerve catheter as a part of their postoperative pain management. this study.

Exclusion Criteria:

* history of hemostatic abnormalities
* chronic pain syndrome
* a foot deformity restricting normal foot movement
* severe liver or renal disease
* a preexisting neurologic disorder
* patient refusal to participate
* the presence of language barrier that prohibits proper communication with patient.
Electroacupuncture and Trancutaneous Electrical Nervous Stimulation (TENS) for Colonoscopy Analgesia

To compare the effectiveness of acupuncture and transcutaneous electrical nervous stimulation (TENS) in reducing patient's discomfort during colonoscopy

Evaluation patient's pain and discomfort during colonoscopy, using two non invasive analgesic methods.

Eligibility Criteria:
Inclusion Criteria:

* all patients scheduled for colonoscopy and in whom deep sedation was not planned will be included in the study

Exclusion Criteria:

* age \> 80 and less than 18 years old, severe cardiac or pulmonary disease, anticoagulant, benzodiazepines, antidepressants, opiates therapies, severe cognitive impairment, uncontrolled hypertension.
Iodine-125 Seed Implantation Therapy for Locally Advanced Pancreatic Cancer

This study evaluates the application of 3D-printed template for iodine-125 seed implantation therapy in patients with locally advanced pancreatic cancer. Half of participants will receive 3D-printed coplanar template, while the other half will receive 3D-printed non-coplanar template.

Dosimetric verification was performed after implantation. Pre- and postoperative D90, V100, and V150 were calculated. The success rate of iodine-125 seed implantation, dosimetric parameters, objective response rate (ORR)，overall survival (OS)，toxicities and quality of life of two treatment regimens and complications were analyzed and compared between the two groups.

Eligibility Criteria:
Inclusion Criteria:

* Age: 18-80 years
* Cytologically or histologically confirmed pancreatic adenocarcinoma
* Inoperable locally advanced pancreatic cancer based on American Joint Committee on Cancer (AJCC) staging system (8th ed) (without distant metastasis)
* Single tumor size≤ 6 cm
* Karnofsky performance score （KPS）≥60
* Estimated survival ≥3 months
* Without other several comorbidity
* Participants must have adequate organ function:

  * WBC≥3×109/L; HGB≥90g/dL; PLT≥50×109/L
  * Aspartate Transaminase (AST)/alanine aminotransferase ( ALT) ≤3 × institutional upper limit of normal
  * Albumin≥3g/dL
  * Total bilirubin ≤3mg/dL
  * PT≤3 × institutional upper limit of normal or INR≤2.3
  * Creatinine ≤1.5 × institutional upper limit of normal
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Patients with other malignant tumors
* History of other anti-cancer therapy, including surgery,radiation, ablation and so on
* Pregnant or lactating women
* Patients with Immunodeficiency disease
* Several heart disease, for example: New York Heart Association (NYHA) class III/IV congestive heart failure，active coronary heart disease and severe arrhythmia
* Uncontrolled hypertension
* Ongoing or active infection (\>grade 2 based on National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) 4.0 edition)
* Active tuberculosis
* Chronic renal insufficiency
* Other organ failure
* History of organ transplantation
* History of severe mental illness